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lnfeCti0nS in the immunocompromised non- rejection is occurring. Tragic cases of disseminated toxoplasniosis 
neutropenic patient have been precipitated by erroneous findings of heart transplant 
rejection in mismatched patients, who subsequently underwent trea- 
inent with high doses of corticosteroids. In liver transplant patients, 
clinical manifestations usually occurred within 3 months of the 
transplantation in each of the cases with diswninated toxoplarniosis. 
Fever, pneumonia and multi-organ failure were observed most 
commonly. In addition to encephalitis, myocarditis and pneumonitis 
due to Toxopiasma have commonly been observed in bone marrow 
transplant patients. The protean manifestations and their relatively 
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Infection with the opportunistic fungus Ptieumocystis rarinii remains a 
significant cause of respiratory morbidity in immunosuppressed 
patients. In the non-HIV-infected immunosuppressed, specific risk 
factors .fur l? carinii pneumonia include use of glucocorticoids 
(=30 mg prednisolone/day or equivalent) and cyclosporin. In HIV- 
infected patients the risk is related to low CD4 lymphocyte counts. 
In 1999 in North America and Europe, I! carinii is now usually only 
seen in those who are unaware of their HIV serostatus at presentation 
with pneumonia or who are intolerant of or non-compliant with 
highly active antiretroviral therapy and/or anti-l? carinii prophylaxis. 
The benchmark for diagnosis of P carinii pneumonia is histocheniical 
(immunofluorescence staining of bronchoscopic alveolar lavage 
(BAL) fluid. Recently, application of PCR,  using P carinii-specific 
primers, to non-invasive samples of mouth rinse has been shown to 
be a highly sensitive and specific method of diagnosis. Quantitative 
P C R  applied to sequential mouth rinse samples may be used to 
monitor response to treatment. 
Genotyping of l? carinii from BAL fluid or mouth rinse shows a 
low frequency of person-to-person transmission of P carinii in case- 
clusters of l? carinii pneumonia and also demonstrates association of 
specific genotypes with disease severity. Mutations in genes which 
are drug targets for dapsone and sulfanierhoxazole (DHPS) and 
atovaquone (cytochronie h) have been described in association with 
sulfa drug and atovaquone prophylaxis failures in HIV-infected 
patients, suggecting the possibility that drug resistance may develop 
with prolonged drug exposure in some patients. 
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Despite the fact that toxoplasmosis is recognized as an opportunistic 
infection in organ transplant recipients, it continues to go undiag- 
nosed as a cause of severe morbidity and mortality in these patients. 
Most often it is not considered in the differential diagnosis of 
infection in organ transplant patients and is first recognized as the 
cause of death at autopsy. Although the brain IS the most common 
organ involved, pneumonitis and myocarditis have been more 
frequently reported in certain organ transplant groups than in patients 
with lyniphoproliferative disorders. Disseminated infection with 
multiple organ involvement has been described in an increasing 
number of patients, most recently in liver transplant recipients. In 
most organ transplant patients, toxoplasmosis is the result of trans- 
plantation of an infected organ (from a seropositive donor) into a 
seronegative recipient. The major exception is the bone marrow 
transplant patient, in whom toxoplasmosis most often is a manifest- 
ation of recrudescence of a latent (chronic) infection. In the heart 
transplant patient, toxoplasmosis usually has occurred in the first 90 
days post-transplant, may resemble rejection and may first be 
diagnosed on endomyocardial biopsy performed to determine if 
uncommon occurrrence in these latter patients contribute to 
difficulties in diagnosis. Unique to the bone niarrow transplant is that 
toxoplasnia serology frequently cannot be relied upon to diagnose the 
infection in the post-transplant state. The risk of toxoplasrnosic in the 
organ transplant patient is sufficiently great to underscore the 
importance of determining Toxoplasnia antibody titers on sera drawn 
prior to transplantation from all recipients and donors. The treatment 
of choice remains the combination pyrimethaniine/sulfadiazine. 
Recently, however, a number of the newer antibiotics have been 
found to have excellent in vitro and in vivo activity against the 
parasite in laboratory studies. Clearly, prevention is most important 
and, at present, is best achieved with pyrimethamine when feasible 
in the post-transplant period. Aspects of diagnosis, treatment and 
prevention will be presented. 
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Invasive fungal infections reinain a substantial cause of morbidity and 
mortality in solid organ transplant recipients and may occur in all 
types of transplant recipients. The fungal species and type\ of 
infection differ, depending on the organ transplanted. Catzdida 
followed by .4zpei$has species are the commonest pathogenr. A 
significant fungal infection develops in 0-20% of kidney recipients. 
10-35% of heart-lung recipients, 6-38%1 of pancrear recipients, 
33-53% of small bowel recipients and 4-4796 of liver recipients. The 
infection is serious, with mortality rates of 10.5-71'%1 for candidosis, 
increasing to 20-1 00% in the case of an aspergillosis. A4spe!yilluj 
species are ubiquitous soil-dwelling molds which, in contrast to 
C a r d i d a ,  often can be isolated from air samples, dust, food 2nd pot 
plants in hospitals. The infection is nosoconiial and ucually acquired 
by airborne transmision. Asperqillus species associated with disease in 
humans are .4. fnmkatus, j a w s ,  .4. n$y and '4. tcrrcvis. I n  solid 
organ transplant recipients, the coninion aspergillus infection is a 
local airway or invasive pulmonary infection, with abscesy formation 
and/or dissemination. Classical second sites for lesions are the central 
nervous syctem, the heart, kidney, liver and spleen. Mediastinitis and 
necrotizing bronchopneumonia have also been described with 
ulceration, necrosis, cartilage invasion and pseudomembrane forrna- 
tion at the site of the bronchial anastomosis. Treatment requires high 
doses of amphotericm B, combined with 5-flucytosin or, at present, 
the use of a lipid formulation of ainphotericin B. So far, no other 
drugs have been considered as first-line therapy. 
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Renal transplantation and infection-focus on 
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CMV is a continuing cause of morbidity in the renal transplant 
recipient. As more high-risk transplantation is performed due to lack 
of suitably matched organs, the incidence of .CMV infection is 
increasing. My talk will focus on the insight that CMV load measures 
can provide in understanding the pathogenesis of CMV disease and 
the interrelationship between viral load in the blood and urine and 
established risk factors for CMV disease such as donodrecipient 
CMV serostatus, augmented immunosuppression, etc. A series of 
investigations in my laboratory has shown, using quantitative PCR 
methods, that CMV load is the most important parameter in CMV 
pathogenesis and accounts for the previous risk factors. The utility of 
these data in the context of antiviral intervention will then be 
discussed-how effective therapy needs to be to suppress replication 
and impact on disease, and the benefitddrawbacks of pre-emptive 
versus prophylactic regimens. I will conclude by discussing recent 
data implicating HHV-7 as a cofactor for CMV disease in renal 
transplant recipients and the possibility that controlled clinical trials 
aimed at inhibiting CMV replication may produce beneficial effects 
through inhibition of other beta-herpesviruses. 
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The importance of multiresistant microorganisms as a cause of 
nosocomial infection in ICU patients has been documented in many 
studies. By now, many Pseudumonar aeruginusa and .4cinetubacter 
baumannii strains are class I cephalosporinase producers and are 
resistant to piperacillin, aztreonam and ceftazidime. Klebsiella 
pneumoniae strains are also increasingly recognized as producers of 
transferable extended-spectrum beta-lactamases which confer resist- 
ance to third-generation cephalosporins. Other multiresistant aerobic 
Gram-negative bacilli include Xanthomonas (Stenotrophomunas) malto- 
philia and akcalkenes. Unfortunately, methicillin-resistant Staphylococcus 
aureus is also more and more frequently implicated as a causative 
pathogen in very sick patients who require ICU care for a long period 
of time. Therefore, the microbiological trends in nosocomial 
infection are evolving towards more resistant and more difficult-to- 
treat pathogens. A large body of evidence strongly supports the 
observation that the indiscriminate use of antimicrobial agents in 
ICU patients has immediate but also long-term consequences, 
contributing to the emergence of multiresistant pathogens and 
increasing the risk of serious superinfections. Virtually all reports 
emphasize that better antibiotic control programs In order to limit 
bacterial resistance are urgently needed in ICUs and that patients 
without true infection should not receive antimicrobial treatment. 
Therefore, it should be made clear to physicians confronted with 
ICU patients clinically suspected of having developed nosocomial 
infection that treating all these patients with new antimicrobial agents 
may lead to overtreatment in a large number of cases and, thus, to 
the rapid emergence of multiresistant pathogens not only in the 
treated patients but also in other patients hospitalized in the same 
m i  t . 
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Medical economic evaluations have been performed for many 
pharmaceutical substances and immunization programs. Study results 
have helped to improve health policy decisions regarding preventive 
immunization and acute treatment. Disease models are used to 
estimate the medical outcomes and cost consequences of alternative 
intervention strategies, not just pharmaceutical treatments. Studies 
indicate that primary prevention is often more efficient in high-risk 
rather than low-risk populations and that secondary prevention tends 
to be more efficient than primary prevention. 
The evaluation of alternative antimicrobial treatments requires 
answers to a sequence of questions: Who needs treatment? How is 
the target population defined? What are the best treatments, doses, 
routes of administration, and duration of treatment? How can the 
expected long-term medical outcomes be estimated for a given target 
population, particularly in the face of only short-term evidence? 
What are the expected cost consequences of alternative treatments? 
Disease models attempt to represent disease processes, based on a 
synthesis of available medical data. They simulate the development of 
diseases for different patient populations under different management 
strategies: extrapolate short-term data and surrogate endpoints to 
long-term clinical outcomes; extrapolate from trial data to popu- 
lation (efficacy to effectiveness) in clinical practice; what-if analyses 
of different assumptions. Additionally, disease models allow us to 
determine the most important efficiency parameter as well as cost 
parameter by sensitivity analysis as well as to direct scarce resources 
to efficient treatments. 
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Non-tuberculous mycobacteria are opportunistic, intracellular 
pathogens whose source is environmental. Infection is associated with 
predisposing conditions: lung disease, alteration in chest architecture, 
or immune deficiency. Lung, skin, lymph node, gastrointestinal, 
disseminated and nosocomial infections have been reported. 
Examples of non-tuberculous mycobacteria causing pulmonary 
infections include Mycubacterium kansasii, M .  avium, M .  intracellulare, 
M. malmoenre and M .  xenopi. Though the epidemiologies of the 
infections differ, hf. marinum, M. haemophilnm and M.  ulcerans have 
all been implicated in skin infections. 111. auium is responsible cervical 
lymphadenitis in children. M. paratuberculosis causes diarrheal disease 
Uohne’s) in cattle and may be responsible for Crohn’s disease in 
humans. Although the majority of disseminated infections in AIDS 
patients are caused by M.  auium, other mycobacterial species, 
including M.  kansasii, Af. malmoense and newly identified species (e.g. 
M. genavense), are responsibie for infection as well. 
One source of non-tuberculous mycobacterial Infection is water. 
iLf. auiurn isolates from water have DNA fingerprints matching those 
of isolates from either human AIDS patients or SIV-infected monkeys 
who drank the water. Outbreaks of M. xenupi and M. ulerans have 
been associated, in time, with recovery from hot water systems or the 
